---
title: "Lanifibranor (IVA337) in Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis: Lifestyle intervention and weight loss"
description: "Formulary evidence on Lanifibranor (IVA337) in Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis: Lifestyle intervention and weight loss. Topics: EASL-EASD-EASO guideline recommendations: weight loss targets, diet quality, and physical activity in adults with MASLD; EASL-EASD-EASO guideline: achievement and maintenance of weight loss; AASLD practice guidance statements: caloric deficit and physical activity; AASLD practice guidance: magnitude of weight loss and its maintenance; 4 further topics. 8 evidence topics quoted from 7 sources."
canonical: "https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/product-information-and-disease-description/lifestyle-intervention-and-weight-loss"
published: "2026-11-18T22:34:49-05:00"
modified: "2026-11-18T22:34:49-05:00"
---

# Lanifibranor (IVA337) in Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis: Lifestyle intervention and weight loss

<a id="heading-2.2.2.1.1"></a>

## 2.2.2.1.1 Lifestyle Intervention and Weight Loss

<a id="topic-2.2.2.1.1-1"></a>

### EASL-EASD-EASO guideline recommendations: weight loss targets, diet quality, and physical activity in adults with MASLD

> “In adults with MASLD, dietary and behavioural therapy-induced weight loss should be recommended to improve liver injury, as assessed histologically or non-invasively (LoE 1, strong recommendation, strong consensus).”
> “In adults with MASLD and overweight, dietary and behavioural therapy-induced weight loss should aim at a sustained reduction of ≥5% to reduce liver fat, 7-10% to improve liver inflammation, and ≥10% to improve fibrosis (LoE 2, strong recommendation, strong consensus).”
> “In adults with MASLD, improving diet quality (similar to the Mediterranean dietary pattern), limiting the consumption of ultra-processed food (rich in sugars and saturated fat) and avoiding sugar-sweetened beverages should be recommended to improve histologically or non-invasively assessed liver injury (LoE 2, strong recommendation, strong consensus).”
> “In adults with MASLD, physical activity and exercise should be recommended to reduce steatosis, tailored to the individual’s preference and ability (preferably >150 min/week of moderate or 75 min/week of vigorous-intensity physical activity) (LoE 1, strong recommendation, strong consensus).”

Source: [European Association for the Study of the Liver (2024)](https://www.journal-of-hepatology.eu/article/S0168-8278%2824%2900329-5/fulltext)

<a id="topic-2.2.2.1.1-2"></a>

### EASL-EASD-EASO guideline: achievement and maintenance of weight loss

> “However, a limited proportion of individuals achieve a weight reduction of ≥5%”
> “In addition, long-term adherence to behavioural changes is often insufficient, as seen in obesity trials”
> “Only a few studies have performed 12-24 month follow-ups, showing a maximal weight loss at 6 months, followed by a gradual weight regain to a net weight loss of about 5% at 12-24 months and partial regain of liver lipid content and stiffness”
> “Further follow-up studies are needed to determine the long-term effectiveness of dietary and behavioural therapy-induced weight loss (including its magnitude) on clinical liver-related outcomes and liver-related mortality (LoE 3, strong consensus).”

Source: [European Association for the Study of the Liver (2024)](https://www.journal-of-hepatology.eu/article/S0168-8278%2824%2900329-5/fulltext)

<a id="topic-2.2.2.1.1-3"></a>

### AASLD practice guidance statements: caloric deficit and physical activity

> “Thus, actionable statements rather than formal recommendations are provided herein.”
> “Patients with NAFLD who are overweight or obese should be prescribed a diet that leads to a caloric deficit. When possible, diets with limited carbohydrates and saturated fat and enriched with high fiber and unsaturated fats (eg, Mediterranean diet) should be encouraged due to their additional cardiovascular benefits”
> “Patients with NAFLD should be strongly encouraged to increase their activity level to the extent possible. Individualized prescriptive exercise recommendations may increase sustainability and have benefits independent of weight loss”

Source: [Rinella et al. (2023a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10735173/)

<a id="topic-2.2.2.1.1-4"></a>

### AASLD practice guidance: magnitude of weight loss and its maintenance

> “Weight loss of 3%–5% improves steatosis, but greater weight loss (> 10%) is generally required to improve NASH and fibrosis”
> “Few patients (≤ 10%) achieve effective weight loss despite structured interventions at 1 year, and fewer than half of these maintain the weight lost 5 years after intervention”
> “Weight loss improves hepatic steatosis, NASH, and hepatic fibrosis in a dose-dependent manner.”

Source: [Rinella et al. (2023a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10735173/)

<a id="topic-2.2.2.1.1-5"></a>

### ADA Standards of Care recommendation 4.25: lifestyle change in adults with type 2 diabetes or prediabetes and MASLD

> “Adults with type 2 diabetes or prediabetes, particularly with overweight or obesity, who have metabolic dysfunction–associated steatotic liver disease (MASLD) should be recommended lifestyle changes using an interprofessional approach that promotes weight loss, ideally within a structured nutrition plan and physical activity program for cardiometabolic benefits B and histological improvement. C”
> “There is consensus that a minimum weight loss goal of 5%, preferably ≥10%, is needed to improve liver histology”
> “Individualized, structured weight loss and exercise programs offer greater benefit than standard counseling in people with MASLD”

Source: [American Diabetes Association Professional Practice Committee (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12690184/)

<a id="topic-2.2.2.1.1-6"></a>

### AASLD updates on resmetirom and semaglutide: lifestyle modification alongside pharmacotherapy

> “Regardless of resmetirom treatment status, best practices in metabolic dysfunction-associated steatotic liver disease (MASLD) management should include comprehensive lifestyle modification (nutrition, exercise, and behavior modification) and optimal control of comorbid metabolic conditions”

Source: [Chen et al. (2025)](https://journals.lww.com/hep/fulltext/10.1097/hep.0000000000001112~resmetirom-therapy-for-metabolic-dysfunction-associated)

> “Lifestyle modification remains the cornerstone of MASLD/MASH management alongside semaglutide.”

Source: [Bansal et al. (2026)](https://journals.lww.com/hep/fulltext/10.1097/hep.0000000000001608~semaglutide-therapy-for-metabolic-dysfunctionassociated)

<a id="topic-2.2.2.1.1-7"></a>

### Weight loss and histology in biopsy-proven NASH: prospective cohort in Havana, Cuba, 293 participants, 261 with paired biopsies at week 52

> “We conducted a prospective study of 293 patients with histologically proven NASH who were encouraged to adopt recommended lifestyle changes to reduce their weight over 52 weeks, from June 2009 through May 2013, at a tertiary medical center in Havana, Cuba.”
> “Paired liver biopsies were available from 261 patients.”
> “At week fifty-two, 88 subjects (30%) had lost ≥5% of their weight.”
> “All patients who lost ≥10% of their weight had reductions NAS, 90% had resolution of NASH, and 45% had regression of fibrosis.”

Source: [Vilar-Gomez et al. (2015)](https://pubmed.ncbi.nlm.nih.gov/25865049/)

<a id="topic-2.2.2.1.1-8"></a>

### Intensive lifestyle intervention: randomized trial in 31 overweight or obese adults with biopsy-proven NASH, 48 weeks

> “Thirty one overweight or obese individuals (Body mass index 25-40 kg/m2) with biopsy proven NASH were randomized in a 2:1 ratio to receive intensive lifestyle intervention (LS) or structured education (control).”
> “After 48 weeks of intervention, participants assigned to LS lost an average of 9.3% of their weight vs 0.2% in the control group (p=0.003).”
> “A higher proportion of participants in the LS group had a reduction of NAS ≥ 3 points or had post treatment NAS ≤ 2 as compared to the control group (72% vs 30%, p=0.03).”
> “Post intervention liver biopsy was completed in 28/31 (90%) of participants, 18/21 (86%) in the lifestyle intervention group and 10/10 (100%) in the control group.”

Source: [Promrat et al. (2010)](https://pmc.ncbi.nlm.nih.gov/articles/PMC2799538/)

## Related pages
- [Lanifibranor (IVA337): Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis) · [Markdown](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis.md)
- [Lanifibranor (IVA337) in Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis: Terms and abbreviations](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/terms-and-abbreviations.md)
- [Lanifibranor (IVA337): Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/executive-summary) · [Markdown](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/executive-summary.md)
- [Lanifibranor (IVA337) in Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis: Product information and disease description](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/product-information-and-disease-description.md)
- [Lanifibranor (IVA337) in Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis: Clinical evidence](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/clinical-evidence.md)
- [Lanifibranor (IVA337) in Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis: Economic information and modeling report](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/economics) · [Markdown](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/economics.md)
- [Lanifibranor (IVA337) in Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis: References](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/references) · [Markdown](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/references.md)
